Total submissions: 2
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| University of Washington Department of Laboratory Medicine, |
RCV000758568 | SCV000887308 | pathogenic | Lynch syndrome | 2018-05-01 | criteria provided, single submitter | clinical testing | MLH1 NM_000249.3:c.131C>A has a 99.6% probability of pathogenicity based on combining prior probability from public data with a likelihood ratio of 26.5 to 1, generated from evidence of seeing this as a somatic mutation in a tumor with loss of heterozygosity at the MLH1 locus. See Shirts et al 2018, PMID 29887214. |
| Ambry Genetics | RCV002386318 | SCV002694784 | likely pathogenic | Hereditary cancer-predisposing syndrome | 2019-12-27 | criteria provided, single submitter | clinical testing | The p.S44Y variant (also known as c.131C>A), located in coding exon 2 of the MLH1 gene, results from a C to A substitution at nucleotide position 131. The serine at codon 44 is replaced by tyrosine, an amino acid with dissimilar properties. In one study, protein functional analysis was performed in assays using a hybrid human-yeast MLH1 gene and p.S44Y demonstrated significantly reduced mismatch repair activity (Ellison AR et al. Nucleic Acids Res., 2004 Oct;32:5321-38). Another alteration at the same codon, p.S44F, has been reported as pathogenic based on identification in individuals meeting clinical criteria for HNPCC/Lynch syndrome, segregation with disease, and deficient mismatch repair activity in functional studies (Bronner CE, Nature 1994 Mar; 368(6468):258-61; Tannergård P, Cancer Res. 1995 Dec; 55(24):6092-6; Salahshor S et al. Lab. Invest., 2001 Apr;81:535-41; de Jong AE et al. Clin. Cancer Res., 2004 Feb;10:972-80; Lagerstedt Robinson K et al. J. Natl. Cancer Inst., 2007 Feb;99:291-9; Takahashi M, Cancer Res. 2007 May; 67(10):4595-604; Drost M et al. Hum. Mutat., 2010 Mar;31:247-53). Based on an internal structural assessment, p.S44Y leads to general local structural disruption of a structurally sensitive region (Guarné A et al. EMBO J., 2001 Oct;20:5521-31). This variant was identified as somatic in conjunction with loss of heterozygosity of MLH1 in Lynch syndrome-related tumors demonstrating MMR deficiency by IHC (Shirts BH et al. Am. J. Hum. Genet. 2018 07;103:19-29; Ambry internal data). This variant was not reported in population-based cohorts in the Genome Aggregation Database (gnomAD). This amino acid position is well conserved through mammals, but not in all available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. |